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Abstract 
 
The purpose of this paper is to extend operations management theory concerning 
efficiency and flexibility trade-offs to the emergent phenomenon of redistributed 
manufacturing (RDM). The study adopts a multiple case design including five small 
and five large pharmaceutical firms. By synthesising the research findings and extant 
literature we propose organisations can gain the efficiency benefits of centralised 
manufacturing and the flexibility advantages of RDM by building an ambidexterity 
capability. To build such a capability, large firms can structurally partition their 
manufacturing and supply management functions, with one sub-unit managing 
centralised production and the other RDM. Small and medium enterprises can build an 
ambidexterity capability by creating the right organisational context, one in which a 
multi-skilled workforce switches between efficient and flexible tasks. This paper 
contributes to theory by explaining the emergence of RDM using an organisational 
ambidexterity lens, laying the groundwork for new theory development in the field. The 
paper contributes to managerial thinking by providing practical examples of how 
managers can build an ambidexterity capability to realise flexibility and efficiency 
advantages. 
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1. Introduction 
Manufacturing systems are in a constant state of evolution. In the 1980s the world 
witnessed a shift from mass production lines to ‘lean’ production systems (Milgrom and 
Roberts 1990; Womack, Jones, and Roos 1990). In the late 1990s agile supply chains 
emerged allowing fast fashion companies to quickly respond to fluctuations in customer 
demand (Christopher 2000; Lee 2004). Then, in the early 2000s, mass customisation 
systems promised companies the ability to efficiently manufacture products for individual 
consumers on a large scale (Pine 1999). Each of these fundamental shifts in manufacturing 
systems has been enabled by significant advances in technology (e.g. Barcodes, Radio 
Frequency Identification).  
Today, a new evolution in manufacturing is taking place. Redistributed 
Manufacturing (RDM) promises organisations the ability to flexibly respond to demand by 
using distributed facilities to manufacture close to the customer. RDM is defined as the 
transformation from a ‘current state’ to a ‘future state’ using new production and 
infrastructural technologies, and involves a radical change in the geographical dispersion 
of production facilities, normally from a high volume centralised model to a lower volume 
dispersed factory model, located closer to the point of use (Srai, Harrington, and Tiwari 
2016, p. 1). A manufacturing system is the arrangement and operation of machines, tools, 
material, people, and information to produce a value-added physical informational, or 
service product whose success and cost is characterized by measurable parameters 
(Cochran and Dobbs 2001 p. 372). 
As with other transformative manufacturing systems that came before, RDM is 
enabled by major technological advancements, particularly in the case of additive 
manufacturing, or, 3D printing. 3D printing creates three-dimensional artefacts through 
layer-by-layer deposition of materials (Ford and Minshall 2015). One advantage of 3D 
printing is that it allows companies to distribute manufacturing to a variety of sites near to 
the point of consumption whilst still maintaining uniform outputs (Ford and Minshall 
2015). One drawback, however, is that RDM fails to capitalise on the efficiency gains that 
are associated with the mass production of goods within a centralised facility.  
The trade-offs that exist between efficient and flexible manufacturing systems is a 
phenomenon long examined by operations management (OM) scholars (see De Meyer et 
al. 1987; Kannan 1998; Grant 1991; Hill 1993; Hayes and Wheelwright 1984; Skinner 
1969, 1985). One group of scholars suggest that companies should pursue either a low cost 
competitive strategy supported by efficient operational processes, or a strategy of 
differentiation supported by more flexible processes (Hill 1993; Markides 2006; Porter 
1980, 1996). According to these scholars, attempting to reconcile two opposing systems is 
likely to result in organisations becoming stuck in the middle, leading to high switching 
costs (Porter 1980, 1996; Markides 2006). However, another group of scholars suggests 
that organisations can manage the trade-offs associated with efficient and flexible 
production systems by developing an ambidexterity capability (Adler, Goldoftas, and 
Levine 1999; Duncan 1976; Gibson and Birkinshaw 2004; Tushman and O’Reilly 1996). 
These scholars believe that ambidextrous organisations tend to be successful precisely 
because they are both efficient in the management of daily business demands and adaptive 
enough to flexibly respond to changes in the business environment (Gibson and Birkinshaw 
2004; Tushman and O’Reilly 1996). 
More recently, the notion of ambidexterity has been extended beyond the boundaries 
of the firm to the supply chain. For example, Kristal, Huang and Roth (2010) find that 
supply chain managers can build practices to gain operational efficiency while 
simultaneously searching for opportunities to gain operational advantages associated with 
flexible processes. Similarly, Blome Schoenherr, and Kaesser (2013) find that 
organizational ambidexterity can enhance the innovation outputs of buyer-supplier 
engagements while Rojo, Llorens-Montes and Perez-Arostegui (2016) find that building a 
supply chain ambidexterity capability can help firms to achieve an optimal level of supply 
chain flexibility.  
These studies demonstrate that OM theory is reaching consensus that efficiency and 
flexibility is not an either-or decision. Instead, OM scholars now acknowledge the 
complementarities between efficient and flexible manufacturing systems and find they can 
co-exist within a focal firm’s supply chain. The purpose of our study is to further extend 
OM theory surrounding efficiency and flexibility trade-offs to the emergent phenomenon 
of redistributed manufacturing. Our aim is to answer the question: how can firms reconcile 
the efficiency advantages of a centralised manufacturing system with the flexibility 
advantages of a redistributed manufacturing system?  
To answer this question we study the pharmaceutical industry; a sector that in the 
past predominately used a centralised manufacturing model to minimise production costs, 
but is now exploring the use of smaller and more agile facilities to support dispersed 
manufacturing models (Srai et al. 2015). We use the manufacturing and supply 
management functions of the focal firm as the units of analysis to understand how new and 
existing manufacturing systems can be integrated. We take an abductive approach 
continuously moving between theory and data to arrive at a robust set of findings 
(Josephson and Josephson 1996; Suddaby 2006). Specifically, we use organisational 
ambidexterity as a theoretical lens to examine empirical data gathered from ten case 
companies in the pharmaceutical industry. 
The remainder of the paper is divided into four sections. The next section reviews 
the discourse surrounding efficiency/flexibility trade-offs and ambidexterity. We then 
provide justifications for the research design, data collection and analysis methods. The 
findings from a multiple-case study of UK pharmaceutical firms are then presented. The 
paper concludes by synthesising the research findings and extant literature to set out a 
framework for future RDM research – laying the groundwork for new theory development 
in the field of RDM. 
 
 
2. Literature Review 
 
2.1 The Flexibility and Efficiency Trade-offs of Manufacturing Systems 
 
Skinner (1969, 1974, 1985), one of the first authors in the OM field to explore efficiency-
flexibility trade-offs, argued that while the role of the manufacturing function is to support 
a company’s strategy, it cannot effectively do so when trying to meet multiple performance 
objectives. Similarly, Hayes and Wheelwright (1984) stressed that the manufacturing 
function should concentrate on one performance objective, be it efficiency or flexibility, to 
achieve optimum results. Building on this notion, Hill (1993) argued that companies should 
set out clear competitive objectives, such as whether to compete based on cost or 
responsiveness, and then develop manufacturing processes to support the delivery of these 
objectives. These authors propose an either-or perspective, suggesting that an organisation 
should select one primary performance objective and then design suitable manufacturing 
systems to enable delivery.  
Such views are supported by leading management scholars such as Porter (1996), 
who argues that companies that try to compete simultaneously on low cost and 
differentiation strategies risk degrading the value of existing activities whilst paying huge 
straddling costs. Other scholars such as Kurke (1988) argue that efficiency requires a 
bureaucratic form of organisation with high levels of standardisation, formalisation, 
specialisation and hierarchy; it is exactly these bureaucratic features that impede the fluid 
process of mutual adjustment required for flexibility (ibid). Markides (2006) supports this 
argument when he states that integrating an innovative new business model within an 
existing business unit can often be difficult because of various trade-offs or conflicts 
between the two ways of doing business (Markides 2006). 
This school of thought has been challenged by another group of scholars who find 
too simplistic the notion that firms must follow an either-or strategy (Adler, Goldoftas, and 
Levine 1999; De Meyer et al. 1987). Due to today’s hypercompetitive environment these 
authors argue it is no longer sufficient for firms to pursue only one objective or strategy 
(Melnyk et al. 2010). In their view, firms should instead pursue multiple strategies but to 
differing degrees to ensure competitive survival  (Schoenherr and Mabert 2011; Reimann 
and Sarkis 1996).  
 
2.2 Ambidexterity in Supply Chains 
 
An organization’s ability to pursue two disparate activities at the same time is termed 
organisational ambidexterity (Adler, Goldoftas, and Levine 1999). Duncan (1976) was the 
first to discuss the notion of structural ambidexterity, suggesting that organisations manage 
the trade-offs between conflicting demands by putting in place dual structures where 
certain sub-units focus on alignment while others focus on adaptation. In their study of the 
Toyota Production System, Adler, Goldoftas and Levine (1999) found that production can 
be both efficient and flexible if the organisation partitions itself to allow some sub-units to 
specialise in routine tasks while other sub-units specialise in non-routine tasks. Doing so 
allows the firm to exploit the cost advantages associated with repetitive routines whilst 
simultaneously exploring for new flexible manufacturing systems during non-routine work 
(Adler, Goldoftas, and Levine 1999). Similarly, Tushman and O’Reilly (1996) discovered 
that a firm can achieve superior performance by competing in mature markets in which 
cost efficiency and incremental innovation are critical, whilst developing new products for 
emerging markets in which experimentation, speed and flexibility are essential.  
More recently, Kortmann et al. (2014) explained that two ambidextrous operational 
capabilities (mass customization and innovative ambidexterity) can fully mediate the 
relationship between strategic flexibility and operational efficiency. They argue that firms 
that emphasize organizational diversification create flexible strategies by investing in 
ambidextrous operational capabilities that yield both radical and incremental production 
innovations (Kortmann et al. 2014). Patel et al. (2012) also examined the role of 
ambidexterity capabilities and found that firms with greater operational ambidexterity 
capabilities are more likely to respond to demand as well as technical and competitive 
uncertainty by pursuing manufacturing flexibility. Organizational Ambidexterity has also 
been found by Tomayo-Torres (2017) to act as enabler across quality, speed, flexibility and 
cost dimensions, therefore driving manufacturing performance  
Gibson and Birkinshaw (2004) placed more importance on creating the right 
organizational context when nurturing an ambidexterity capability. They suggest senior 
management teams can establish an organisational context that empowers employees to 
make their own choices as to how they divide their time between alignment (efficient) and 
adaptability-oriented (flexible) activities. Such an context is created by informally 
encouraging employees to strive for ambitious objectives (stretch), to meet all expectations 
generated by their explicit or implicit commitments (discipline), to lend assistance and 
countenance to others (support) and to rely on the commitments of each other (trust) 
(Gibson and Birkinshaw 2004).  
Common across much of the ambidexterity literature is an examination of the trade-
offs between efficiency and flexibility within the boundaries of the firm. Only recently has 
a handful of authors sought to understand how organisations achieve ambidexterity outside 
of a firm’s boundaries; in the supply chain (e.g. Blome, Schoenherr, and Kaesser 2013; 
Kristal, Huang, and Roth 2010). Kristal, Huang and Roth (2010) define supply chain 
ambidexterity as a manufacturing firm’s strategic choice to simultaneously pursue both 
supply chain exploitation (efficiency) and exploration (flexibility) practices (Kristal, 
Huang, and Roth 2010 p. 415). Im and Rai (2008) found that knowledge sharing leads to 
relationship performance gains and that such sharing is enabled by the ambidextrous 
management of buyer-supplier relationships. Blome, Schoenherr and Kaesser (2013) found 
that buyers can gain synergistic benefits by pursuing both contractual supplier 
relationships, often associated with cost efficiencies, and relational engagements, which 
provide flexibility benefits. Rojo, Llorens-Montes and Perez-Arostegui (2016) move 
beyond the buyer-supplier dyad to identify that building a supply chain ambidexterity 
capability can help firms to achieve an optimal level of supply chain flexibility. Likewise, 
Lee and Rha (2016) find that supply chain ambidexterity is important as firms mitigate the 
negative impact of supply chain disruptions, thereby enhancing business performance.  
By studying the efficiency/flexibility debate over the decades it becomes evident that 
OM theory is converging on the opinion that a firm’s supply chain can be both efficient 
and flexible – or ambidextrous. However, we are no closer to understanding how a focal 
firm can realize the efficiency benefits of a centralised manufacturing system and the 
flexibility benefits of RDM. The purpose of this paper is to extend OM theory concerning 
efficiency and flexibility trade-offs to the emergent phenomenon of RDM. The steps we 
took to examine the RDM phenomenon are now explained in greater detail.  
 
3. Research Design 
The researchers took an abductive approach to answer the research question, moving back 
and forth between theory and data (Suddaby 2006). Specifically, we used organisational 
ambidexterity as a theoretical lens and gathered data on a current trend in the 
pharmaceutical industry: firms maintaining centralised manufacturing whilst building 
smaller and more agile facilities to support dispersed manufacturing models (Srai et al. 
2015).  
We followed the advice of Yin (2014) and used a case study research design because 
the research question has a ‘how’ framing and examines a recent phenomenon about which 
relatively little is known. A case study design is ideally suited to our investigation because 
it lends itself to early, exploratory investigations in which the variables are still unknown 
and the phenomenon (i.e. RDM) is not at all understood (Voss, Tsikriktsis, and Frohlich 
2002). We selected a multiple, over a single, case study design as it offers more 
opportunities for in-depth data gathering and analysis (Dyer and Wilkins, 1991). Moreover, 
a multiple case design allows for both within- and across-case comparisons, and is often 
considered more robust then single-case designs (Yin, 2014).  
Many of the leading studies on organisational ambidexterity have used case studies 
of large multi-national enterprise (MNE) firms (see Tushman and O’Reilly 1996). The 
particular focus on large MNEs is interesting because small and medium enterprises 
(SMEs) compete in the same hypercompetitive markets as multi-nationals and require the 
same ability to switch between efficient and flexible processes. Therefore, we extended our 
sampling frame to include MNE and SME pharmaceutical firms, with one company 
representing one case.  
Our sampling logic was to conduct preliminary interviews with key experts at a UK 
pharmaceutical policy body. Drawing on their in-depth knowledge about the UK 
pharmaceutical industry, these experts helped identify case companies that could assist in 
answering the research question. Based on their advice, and to allow comparisons 
according to firm size, we studied five MNEs and five SMEs. The policy experts introduced 
us to key contacts at the case companies and we then used a snowball sampling logic to 
identify potential interviewees. Snowball sampling is a non-probability sampling technique 
in which existing subjects recruit future subjects from among acquaintances in their social 
network until the desired sample size is reached (Morgan 2008). A potential drawback of 
convenience sampling is that the sample may not be representative of the population. 
However because of confidentiality concerns, the researchers found the only way to gain 
access to prospective interviewees was through fellow employees at each case company.  
We accounted for construct validity, internal validity, external validity, and 
reliability throughout the research process (Gibbert, Ruigrok, and Wicki 2007; Yin 2014). 
To enhance construct validity, the researchers interviewed key informants and used a 
triangulated data collection approach including semi-structured interviews, focus groups 
and secondary data. Triangulation improves the validity of research findings, as it allows 
the researcher to see that multiple sources of data have led to the same results (Bogdan and 
Biklen 2007). Triangulation also limits confirmation bias, which is the tendency of people 
to favour information that confirms their beliefs or hypotheses (Plous 1993).  
Key informants were interviewed including senior supply chain executives, supply 
chain consultants and managing directors, each of whom could give informed comment on 
their company’s manufacturing systems and supply chains (see Table 1). Expert opinion 
was also gathered from leading academics in the fields of innovation, additive 
manufacturing, life sciences and pharmaceuticals. Twenty-five semi-structured interviews 
were conducted, each lasting between forty-five minutes and one hour. Interviews were 
tape-recorded and transcribed verbatim. Transcriptions were sent to interviewees for 
review and amendment. A total of twenty-two hours of interview recordings and 375 pages 
of transcripts were collected. 
 
 
-Insert Table 1 Here- 
 
 
The interview findings were corroborated through a series of eight focus groups. Thirty 
experts in RDM from industry and academia were invited to a one-day knowledge 
exchange event at the University of Sussex in March, 2016. During the event, participants 
were split into focus groups where they were challenged to identify the enablers and 
barriers of adopting RDM systems in pharmaceutical supply chains. 
The cumulative findings were then objectively verified using primary and secondary 
data sources. Primary documentation gathered from the case companies included new 
technology business cases and procurement and supply chain strategy documentation. 
Secondary data sources included websites, policy documents and annual reports. Data 
collection stopped when a point of theoretical saturation had been reached or, more 
specifically, when additional data did not provide new information or understanding 
(Eisenhardt 1989). 
To enhance internal validity, the researchers followed the advice of Braun and Clarke 
(2006) and used a process of pattern matching and explanation building, considering rival 
explanations throughout the data analysis process. Using thematic analysis techniques, the 
researchers adopted a pattern matching logic to group similar codes together and to identify 
first-order descriptions, or themes. The initial coding structure used to analyse the data is 
shown in Table 2 and includes the first order descriptions of structural ambidexterity and 
contextual ambidexterity. When analysing the data, the researchers also considered 
potential complementarities between an efficient and flexible manufacturing system.  
 
 
-Insert Table 2 Here- 
 
 
Through an iterative process of analysing transcripts and revising the coding template, the 
researcher arrived at a final template that provided a robust explanation of the cases. NVivo 
10 software was used to code the interview transcripts, focus group notes and company 
documentation. 
The researchers also took steps to enhance external validity. Rather than attempting 
to generalise the findings to a wider population, as with statistical generalisation, the 
researchers generalised the findings to a broader theory, a process called analytical 
generalisation (Yin 2014). Specifically, the researchers set out to augment organisational 
ambidexterity theory by examining the RDM phenomenon and the inherent trade-offs 
companies face when adopting such a system. 
To enhance reliability, the researchers established a chain of evidence throughout the 
data collection and analysis process by creating a case study protocol and case study 
database (Ellram 1996). Providing a chain of evidence enhances reliability by allowing 
future researchers to follow the steps taken by the researcher and to arrive at the same or 
similar conclusions (Ellram 1996; Yin 2014). Table 3 provides a summary of the steps 
taken to enhance the validity and reliability of the findings. 
 
 
-Insert Table 3 Here- 
 
4. Research Findings 
During data analysis, a distinct difference in opinion emerged between managers working 
at large MNEs and those working at SMEs. The following section teases out these 
differences by first considering the findings that relate to structural ambidexterity with 
responses split by MNE and SME managers. The findings are further informed by expert 
academic opinion. 
 
4.1 Exploiting the Efficiency Advantages of Centralised Production 
During the interviews, it emerged that all MNE managers (MNE 1-5) had a strong 
preference for maintaining the centralised manufacturing model due to the low per unit cost 
of production and the high sunk costs of facilities and equipment. MNE managers 
repeatedly mentioned that their companies had invested heavily in an efficient, centralised 
manufacturing system designed to produce small molecule tablets and generic pills at the 
lowest possible cost. These views are expressed in Table 4 as follows: 
 
 
-Insert Table 4 Here- 
The consensus of MNE managers was that the current means of centralised 
production are so cost effective that their companies would remain focused on exploiting 
these cost advantages (see Table 3). A review of business case documentation from MNE 
1-5 revealed that when these companies are considering a new technology, the innovation 
must demonstrate cost savings over current technologies to be adopted. As MNE’s are 
intensely cost focused, it becomes difficult to make a convincing business case for the 
adoption of a more flexible and responsive manufacturing system such as RDM, thereby 
confirming our interview and focus group findings.  
At the same time, interviews with supply chain and additive manufacturing 
academics suggest MNE manager’s particular focus on the per-unit production cost of 
centralised manufacturing may, in fact, be misguided. When discussing the trade-offs 
between centralisation and re-distribution, one academic expert stressed that instead of 
focusing on per-unit production costs, firms should instead consider total system costs: 
 
‘That per-unit production cost is not what you should be looking at, it is 
the total system cost that is important…half the inventory in the warehouse 
is going to go to landfill because it’s not being used. The inefficiency in 
the supply chain is a cost that is often forgotten.’  
- Supply Chain Management Academic Expert  
 
The preceding quote stresses that while the centralised model can produce a generic pill at 
a very low cost, the system is underpinned by significant amounts of inventory. Typically, 
inventory in a pharmaceutical supply chain equates to thirty to ninety percent of annual 
demand, with anywhere between four and twenty-four weeks’ worth of finished good 
stocks being held at any one time (Shah 2004). Indeed, the top twenty-five pharmaceutical 
companies are said to hold inventory in the range of $100-150 billion at any one time 
(Harrington and Srai 2014). Not only do MNEs have high inventory carrying costs, they 
also face high instances of inventory write-downs due to expired or unwanted stock 
(Harrington and Srai 2014; Shah 2004). Interestingly, a review of business cases at MNE 
1-5 showed that these companies considered the fixed costs of plant and equipment and 
variable costs such as labour and raw materials when considering new technologies. 
However, we did not find a consideration of the inventory carrying costs associated with 
current production technologies and whether new technologies or manufacturing systems 
could reduce inventory holdings. When one considers the total system cost of centralised 
production, including inventory carrying costs across the supply chain, it becomes easier 
to make a convincing business case for the adoption of redistributed manufacturing 
systems. 
 
4.2 Theme 2: Exploring the Flexibility Advantages of RDM 
SME managers (SME1-5) were found to be more open to the idea of utilising an RDM 
system than were their MNE counterparts. The findings suggest this was primarily because 
SMEs managers prioritised flexibility and responsiveness over cost. One interviewee at 
SME1 discussed the importance of locating production close to the point of need as it 
allows a quick and flexible response to customer demand (see Table 5).  
Academic experts also highlighted the many benefits of using 3D printers in 
distributed production facilities. Some of the advantages include quicker changeover times, 
lower retooling costs and the ability to personalise medicines for patients. 3D printing 
permits a wide range of product specifications to be created on one machine; this capability, 
coupled with reduced need for retooling or line changeovers, enhances speed and embeds 
flexibility into the production process.  
 
 
-Insert Table 5 Here- 
 
 
The quotes in Table 5 suggest that using 3D printing within an RDM system allows for the 
personalisation of medicines, an emergent and highly lucrative market in the 
pharmaceutical industry. As highlighted by Srai et al. (2015) in their paper about the future 
of the pharmaceutical industry, advances in personalised medicines will require product 
customisation that makes the batch-centric production models of today incapable of 
economically supplying product varieties at the smaller volumes required, and at the speed 
increasingly demanded by end-users, without costly inventory holdings. As the RDM 
system locates production close to the customer, redundant nodes in the supply chain are 
removed, thereby reducing the need for buffer stock. Moreover, the production of 
personalised medicines within an RDM system creates the potential for increased profit 
margins, offsetting the higher set-up and running costs of the RDM model.  
Up until this point, centralised manufacturing and RDM have been cast as two 
opposing systems. Yet, as the researchers continued collecting and analysing data, new 
findings emerged that indicated the two systems should not be seen as substitutes, but 
instead as complements to one another. 
 
4.3 Theme 3: Complementarities between Centralised Manufacturing and RDM 
 
Despite its many advantages, the majority of academic and managerial interviewees felt 
that RDM is not likely to entirely replace centralised manufacturing. Instead, most 
interviewees believed the two systems should be seen as complementary, a sentiment 
captured in the following quote:  
 
Many evangelists in this industry say ‘3D printing is a substitute technology 
to others’. However, the more conservative approach is to say ‘okay, 3D 
printing technology will be some sort of complement to actual manufacturing 
lines’.                                           -Academic Expert 1- Additive Manufacturing 
 
The preceding quote suggests 3D printing is likely to be only one technology in the 
spectrum of manufacturing technologies already in use by most MNE firms. As RDM is 
not likely to totally replace centralised production, it becomes imperative to understand 
how RDM can complement the centralised system.  
During the focus group sessions, the researchers encouraged participants to explore 
potential complementarities between RDM and centralised production. As with the 
interviewees, the general consensus of focus group participants was that an RDM system 
does not make economic sense for the mass production of small molecule and generic drugs 
due to the sunk costs and low production prices of the centralised system. Focus group 
members felt that RDM is more applicable to the production of personalized medicines 
including advanced therapy medicinal products (ATMPs), large molecule and biological 
drugs. This group of medicines is more costly to manufacture and tends to have higher 
profit margins, thus more readily justifying the high overhead costs of distributed facilities 
and initially expensive 3D printing technology. Moreover, these types of products tend to 
be highly personalised and targeted at small patient populations, a market ideally suited to 
the RDM model. The potential complementarities between centralised manufacturing and 
RDM as seen by MNE and SME managers are shown in Table 6.  
 
 
-Insert Table 6 Here- 
 
 
The quotes in Table 6 suggest that RDM is best suited to the production of high value, 
personalised medicines targeted at small patient populations such as advanced therapeutics 
(ATMPs) and gene therapies. Other potential applications of an RDM system include the 
manufacture and distribution of compound products, such as infusion bags that are 
uniquely tailored to the patient. Pharmaceutical firms are hesitant to develop compound 
products through conventional means due to the prohibitively high costs associated with 
carrying out stability studies and gaining regulatory approval each time the 
product/packaging mix is altered. 
Late-stage dispensing also emerged as a suitable RDM application. In the UK, the 
Royal Pharmaceutical Society has recently permitted decentralised dispensing, opening up 
the possibility of hospital pharmacies using 3D printing to produce drug combinations. 
Such a distributed dispensing system would be in marked contrast to the current process in 
which complete pill packs are received from the manufacturer, and hospital staff then de-
blister the packs into small personalised packages, generating excessive waste throughout 
the process (see Table 6). 
The production of radioactive pharmaceuticals was seen as another potentially viable 
option which, in effect, currently uses a RDM model. In the radio pharmacy model, a 
hospital pharmacist prepares the radioactive injectable on-site, allowing it to be 
administered to a patient in a matter of hours before it dissipates. Additive manufacturing 
could complement such a model with the product created on-site and administered 
immediately, based on patient need (see Table 6).  
Finally, the Operations Director at MNE5 stressed that using 3D printers within an 
RDM system would allow for the creation of poly-pills, which contain multiple active 
ingredients within one pill. While some focus group participants felt that the validation and 
regulation of combining multiple actives into one pill would prove challenging, others saw 
poly-pills as the future of the pharmaceutical industry (see Table 6).  
Despite the researcher’s attempts to identify passages of text relating to the 
contextual ambidexterity themes of alignment and adaptability, none could be found in the 
data. The researchers specifically looked for passages of text mentioning terms such as 
discipline, support, trust, employee empowerment, judgement and multi-skilled 
employees; however these concepts were not mentioned by the interviewees or focus group 
participants. Furthermore, a review of secondary documentation at MNEs and SMEs, 
including Human Resource Management policy documents and annual reports, did not 
reveal data relating to the five aspects of contextual ambidexterity. This is most likely 
because the majority of the companies studied are yet to adopt an RDM system and have 
therefore not established the internal structures and management mechanism necessary for 
a contextually based ambidexterity capability. As many firms are still in a pre-adoption 
phase, we now synthesize the research findings and extant literature to propose ways in 
which MNE and SME firms can adopt an RDM system.  
 
 
 
 
5 Framework for Future RDM Research 
The following section draws on the literature and case study findings to set out a research 
agenda for the emergent topic of RDM. The research agenda is based on three propositions 
that can be tested by researchers during future studies of RDM. Our research findings 
indicate that RDM is still in a pre-adoption phase, with most managers still considering 
whether to embrace a distributed mode of manufacturing. The data revealed a preference 
of MNE managers to maintain the centralised manufacturing model due to cost advantages, 
whilst SME managers more readily recognized the flexibility advantages of the RDM 
model. Importantly, both MNE and SME managers were able to recognize the 
complementarities that exist between the two models. Table 7 presents a cross-case 
comparison of the codes that fall under the three themes of efficiency, flexibility and 
complementarities. 
 
 
-Insert Table 7 Here- 
 
 
 
The codes contained in Table 7 indicate that organizational size influences how managers 
are likely to foster an ambidexterity capability. MNEs have an employee base numbering 
in the tens of thousands with intricate organizational hierarchies, leading to significant 
levels of complexity (Adler 2011). Due to such complexity, creating an organisational 
context that allows a multi-skilled workforce to quickly switch between alignment 
(efficient) and adaptability (flexible) tasks may prove prohibitively difficult.  To overcome 
such complexity, we suggest that MNE managers are more likely to build an ambidexterity 
capability using structural partitioning.  
The general consensus of MNE managers was that the high over-head costs of 
distributed facilities are only justifiable for low volume, high margin and customizable 
products such as gene and cell therapies, ATMPs, large molecule drugs and biologics. 
MNE managers are therefore likely to maintain the production of small molecule and 
generic drugs within centralised facilities and, as new trends such as personalised 
medicines emerge, consider more flexible manufacturing systems such as RDM. The 
structural partitioning in MNE’s is therefore expected to occur according to product type. 
The Adler, Goldoftas and Levine (1999) study of the adoption of lean management 
systems identified that novel forms of organizational partitioning enable differentiated 
subunits to work in parallel on routine (efficient) and non-routine (flexible) task. Toyota’s 
subsidiary reallocated responsibilities across partitions, in particular through job 
enrichment for workers and more active involvement of suppliers (Adler, Goldoftas, and 
Levine 1999). Like with lean, we suggest that RDM adoption by MNEs will be enabled by 
structurally partitioning the manufacturing function into two sub-units. One sub-unit of the 
manufacturing function would oversee the efficient production of standardised products 
such as generics and small molecule drugs within a centralised manufacturing systems. The 
other sub-unit would be responsible for the flexible production of personalised medicines 
within a re-distributed system (see Figure 1).  
 
 
-Insert Figure 1 Here- 
 
 
Duncan (1976) expresses a note of caution however, stating that partitioning can lead to 
parochial, self-interested subunit behaviour, multiplying the management overhead 
required to reconcile intra-organizational conflict. To counteract such parochial practices, 
we stress that, once partitioned, the two sub-units must share knowledge and best practice. 
By doing so, we propose the focal firm will benefit from enhanced flexibility and 
efficiency. The following proposition is thus advanced: 
 
Proposition 1: Structurally partitioning the manufacturing 
function into centralised manufacturing and RDM sub-units will 
lead to enhanced flexibility and efficiency for MNEs. 
 
We observe that MNE firms need to extend partitioning to the supply chain because the 
majority of primary and secondary materials used in pharmaceutical products come from 
suppliers. Complexity plagues MNE supply chains due to a high numbers of suppliers, 
often numbering in the thousands, as well as multiple supplier tiers (Prater, Biehl, and 
Smith 2001). Roerich and Lewis (2014) find that as systemic complexity increases in the 
supply chain so does the focal firm’s reliance on contractual governance mechanisms. They 
argue that the use of simplified contractual governance in the form of working agreements 
combined with relational governance, such as inter-personal relationships, can be effective 
in counteracting complexity. Similarly, Kreye, Roehrich and Lewis (2015) find that as 
service complexity increases so does the level of relational capability development. Well-
developed relational capabilities, in turn, prevent conflicts and promote the exchange of 
information (Kreye, Roehrich, and Lewis 2015). Cao and Lumineau (2015) also find 
complementarities between formal contracts and relational governance mechanisms and 
argue that contracts, trust, and relational norms jointly improve satisfaction and 
relationship performance. 
We suggest that to overcome complex supply chain structures, MNE firms should 
begin by partitioning the area of the business responsible for supplier management, such 
as the procurement or supply chain management unit. One subunit of the supply 
management function would be responsible for the centralised manufacturing system while 
the other oversees the RDM system (see Figure 2).  
 
 
-Insert Figure 2 Here- 
 
 
Figure 2 shows that the RDM sub-unit is responsible for controlling the flow of active 
ingredients and powders to local production facilities and, if required, any onward 
distribution to the patient. The local manufacturing site may be a hospital, as in the case of 
compound infusion bags, or a pharmacy, as in the instance of personalised drug 
combinations (poly-pills) for patients. The focal firm may also choose to have local 
production sites around the country to distribute personalised medicines (i.e., gene 
therapies) directly to patients. After diagnosing the patient, the personalised medicine 
would be produced on-site using 3D printing technology (see Figure 2). The centralised 
manufacturing sub-unit would focus on driving cost efficiencies with suppliers using 
contracting mechanisms. The RDM subunit would use relational mechanisms such as trust 
and collaboration to enhance flexibility in the supply network. We therefore propose the 
following: 
 
Proposition 2a: Structurally partitioning the supply management 
function into centralised manufacturing and RDM sub-units will lead 
to enhanced flexibility and efficiency for MNEs. 
 
Proposition 2b: Effective partitioning of the supply management 
function will be enabled by using contracting mechanisms to oversee 
the centralised manufacturing system and relational governance 
mechanisms to manage the RDM system 
 
While large resource pools allow MNEs to operate two manufacturing systems in parallel, 
we propose that SMEs should take a different approach. One advantage of having fewer 
employees is that SMEs are better able to create a multi-skilled workforce able to switch 
between alignment (efficiency) and adaptability (flexibility) tasks. Instead of partitioning 
based on product type, we propose that SME production and supply managers can oversee 
the production of high volume, low margin products in a centralised facility whilst 
simultaneously managing the production of highly customizable products in distributed 
facilities (see Figure 3). 
 
-Insert Figure 3 Here- 
 
 
According to Gibson and Birkenshaw (2004) creating the right organizational context for 
ambidexterity requires managers to follow four steps; 1) to create informal routines that 
prompt employees to stretch for ambitious objectives; 2) to meet all expectations in a 
disciplined manner; 3) to support team members in their daily roles and; 4) to create an 
environment of trust between team members. Figure 3 shows that the centralised and RDM 
facilities would be kept physically separate, meaning the production and supply manager 
would need to facilitate fluid communication, trust and teamwork between the operational 
employees at the respective manufacturing sites. In the RDM system, manufacturing would 
occur across a range of distributed facilities including hospitals, pharmacies or facilities 
owned by the focal firm. The centralised production system would run in parallel to the 
RDM system and also be managed by the production and supply managers. We therefore 
propose the following: 
 
Proposition 3a: By creating an organizational context based on the goals of trust, 
support, stretch and discipline, SME production and supply managers can switch 
between the management of a centralised and redistributed manufacturing system.  
 
Proposition 3b: By building a contextually based ambidexterity capability SMEs can 
gain the efficiency advantages of a centralised manufacturing system and the 
flexibility benefits of a redistributed manufacturing system. 
 
 
 
 
 
 
 
 
 
6 Contribution, Limitations and Future Research Directions 
We now conclude with a discussion of the paper’s theoretical and managerial contributions 
and potential methods for testing the propositions in future RDM studies. 
 
6.1 Theoretical Contribution 
 
The purpose of this paper is to extend OM theory concerning flexibility and 
efficiency trade-offs to the emergent area of RDM. The paper makes a theoretical 
contribution by creating a future research agenda for RDM consisting of three propositions. 
Our examination of the pharmaceutical industry suggests MNEs will continue with 
efficient, centralised manufacturing systems and then as new markets emerge, including 
personalised medicines, begin to adopt more flexible manufacturing systems such as RDM. 
We posit that MNEs can build an ambidexterity capability by structurally partitioning their 
manufacturing unit and mirroring this segmentation in the supply management function. 
Suppliers to the centralised systems will be governed by formal contracting mechanisms to 
realize cost efficiencies, while suppliers to the RDM system will be governed by relational 
mechanisms such as collaboration and trust to gain flexibility advantages. 
Although SMEs have smaller resource pools than their MNE counterparts, lower 
levels of complexity can act in their favour. Fewer employees and a flatter organisational 
hierarchy are likely to make it easier to create a multi-skilled workforce able to switch 
between routine and non-routine tasks. SME managers can thus build an ambidextrous 
organisational context by implementing formalised training procedures to develop a multi-
skilled manufacturing and supply management function and by using informal mechanisms 
to instil discipline, support and trust amongst teams (Gibson and Birkinshaw 2004). 
Ambidextrous production and supply managers can efficiently manage suppliers to the 
centralised manufacturing systems using formalized contracting mechanism and encourage 
flexibility by using relational governance mechanisms with suppliers to the RDM system. 
 
6.2 Managerial Contribution 
 
This paper challenges managers to not see efficiency and flexibility as an either-or trade-
off, but instead as complementary. The paper provides MNEs managers with practical 
examples of how their manufacturing and supply management functions can be partitioned 
to pursue both efficiency and flexibility objectives. SME managers are encouraged to 
create a multi-skilled manufacturing and supply management team able to switch between 
alignment (efficient) and adaptability (flexible) processes.  
The structurally partitioned model suggested for MNEs is inherently different than 
the paradigms of ‘leagility’ and mass customisation. These two concepts advocate 
switching between routine and non-routine production processes within the same facility. 
Instead, we suggest that the centralised manufacturing system and the RDM system are 
kept separate using discrete facilities. The centralised manufacturing sub-unit exploits the 
economies of scale associated with manufacturing within centrally located facilities whilst 
the RDM sub-unit explores the flexibility advantages of being close to the patient and 
delivering personalised medication via distributed facilities.  
 
6.3 Research Limitations 
 
The authors acknowledge that limitations exist with the current paper. We do not claim that 
our findings are generalisable to wider populations or other industries (i.e. statistical 
generalisation). Instead, we aim for analytical generalisation by abstracting the findings to 
a broader theory; organizational ambidexterity (Yin 2014). Future researchers could 
generalise the findings to a wider population by testing the propositions using quantitative 
techniques such as surveys or questionnaires. The current study is also limited by its use of 
qualitative data, which is susceptible to researcher bias (Eisennhardt 1989). Following the 
advice of Yin (2014), the researchers took steps to reduce bias and improve the validity 
and reliability of the findings. Specifically, we followed a detailed case study protocol, 
designed a case study database and checked case findings with key informants. Despite 
these measures, the researchers acknowledge that bias may still be present in the 
interpretation of findings. 
 
6.4 Future Research Directions 
 
As RDM is still in the pre-adoption phase, there is much work to be done on this important 
topic. To assist in this endeavour, our paper sets out a future research agenda for RDM. 
Our findings suggest a primary reason for the slow uptake of RDM is that many people 
view it as a disruptive manufacturing system. Instead, we suggest that RDM should be seen 
as complementary to existing centralised production systems; best suited to low volume, 
high margin and personalized products. Our framework for future RDM research sets out 
three propositions where centralised manufacturing and RDM act as complements. In the 
near term, we challenge future researchers to test our propositions using case studies either 
in the pharmaceutical sector, or other industries. In the medium to long term, once RDM 
systems are more widely adopted, we challenge researchers to test the propositions using 
quantitative methods such as surveys or questionnaires.   
Future researchers could also extend our study beyond the focal firm to examine how 
MNE firms structurally partition their supply chains using contracting and relational 
mechanisms.  Such a study would require researchers to collect data from multiple supply 
chain tiers. Researchers could also use a network perspective to investigate how contracting 
and relational governance mechanism can enable an ambidextrous supply network. 
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Table 1: Case company background 
Case  Area of Expertise # of 
employees 
# of 
interviews 
Company 
turnover 
Interviewee Position(s) 
MNE1  R&D and manufacture of 
medicines and consumer 
healthcare products  
+10,000 2  £25-50bn -Supply chain 
transformation lead, 
-Global procurement 
transformation lead 
MNE2  Biopharmaceutical R&D 
and manufacture of 
medicines, consumer 
healthcare products and 
vaccines 
+10,000 3 £1-5bn -Production Director,  
-Director Global 
Warehousing,  
-Global Operations 
Procurement Director 
MNE3  Develops, manufactures 
and sells pharmaceutical 
and biotechnology products 
+10,000 2 £25-50bn -Senior Director  
-Vice President of Supply 
Operations 
MNE4  R&D and manufacture of 
prescription drugs  
+10,000 3 £1-5bn -Commercial Director, -
Commercial Manager, -
Director Group 
Procurement 
MNE5  Develops, manufactures 
and sells biopharma 
products 
+10,000 1 £25-50bn -UK Operations Director 
SME1  Immunotherapy R&D and 
manufacture 
100-1000 1 £25-50mil Operations Director 
SME2  Pharmaceutical 
Consultancy 
100-1000 1 Not 
available 
Process Engineer 
SME3  Pharmaceutical 
Consultancy  
<100 1 Not 
available 
CEO 
SME4  Distance Selling pharmacy  <100 1 Not 
available 
Director of Business and 
Product Development 
SME5  Advisers to pharmaceutical 
policy groups and UK 
government 
<100 1 Not 
available 
Managing Director 
Academic 
Experts 
Expertise: additive 
manufacturing, supply 
chain management, 
innovation, life sciences 
Not 
applicable 
7 Not 
applicable 
Senior 
Lecturer(s)/Professor(s) 
Policy 
Experts 
Experts in informing UK 
pharmaceutical policy 
Not 
applicable 
2 Not 
applicable 
Director, Project Manager 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Initial Coding Template 
Theory First Order 
Descriptions 
Themes Coding Identifiers 
 
 
 
 
 
 
Organizational 
Ambidexterity 
 
 
 
Structural 
Ambidexterity 
Exploitation  Efficiency – cost focus 
Exploration  Flexibility– responsiveness 
focus 
Complementarities 
between efficiency 
and flexibility 
 Potential synergies between 
efficient and flexible 
manufacturing systems  
 
 
Contextual 
Ambidexterity 
 
 
Alignment and 
Adaptability 
 Interaction of stretch, discipline, 
support, and trust 
 Set of processes or systems that 
enable individuals to make their 
own judgments about how to 
divide their time between 
conflicting demands for 
alignment and adaptability 
 
 
 
Table 3: Measures taken to enhance validity and reliability 
Quality of 
Research 
Design 
Case Selection and 
design 
Data Collection  Data Analysis  
Construct 
validity 
Not applicable -Triangulated data collection 
strategy-interviews, focus groups, 
primary and secondary 
documentation (Yin, 2014) 
-Use of highly knowledgeable 
informants considered experts in 
their particular area (Eisenhardt, 
1989) 
-Data analysis in parallel to 
interview phase to be 
receptive to new results 
(Eisenhardt, 1989.) 
-Establish and maintain a 
chain of evidence – case 
study protocol and database 
(Ellram, 1996; Yin, 2014) 
-Draft reports viewed by key 
informants (Ellram, 1996) 
Internal 
validity 
-Cross case 
comparisons (Yin, 
2014) 
-Use of highly knowledgeable 
informants considered experts in 
their particular area (Eisenhardt, 
1989)  
-Multiple respondents (Ellram, 
1997) 
-Pattern matching among 
cases (Yin, 2014) 
-Active search for 
alternative explanations 
(Braun and Clarke, 2006; 
Yin, 2014) 
External 
validity 
-Comparative 
multiple case study 
approach (Ellram, 
1996, Yin, 2014) 
-Gathering data on the case context 
(Gibbert et al. 2008) 
-Consideration of case 
context (Johns 2006) 
-Extensive intra-case 
analysis (Eisenhardt, 1989) 
-Analytical generalization   
(Yin, 2014) 
Reliability -Established a chain 
of evidence 
including case study 
protocol and 
database (Ellram, 
1996, Yin, 2014) 
-Semi-structured interview guide 
included in case study protocol 
(Yin, 2014) 
 
-All interview transcripts 
analysed by interviewers 
(Yin, 2014) 
 
 Table 4: Theme 1: Exploiting the cost efficiencies of centralized manufacturing 
Code MNE Manager 
Current business model 
based on large volumes 
and low variety-too 
expensive to move to 
RDM model 
‘Why would you try to adapt a mass-volume, low variety business 
model to provide customised medication? We're so far away from 
that … it takes so much investment’ --Supply chain transformation 
lead MNE1 
Centralized 
manufacturing offers 
economies of scale 
‘You're almost better, if you can, to produce a larger volume, with a 
fixed head count because the moment you branch out to doing the 
same thing and replicating it in another market, it increases your 
costs.’ – Global operations director- MNE 2 
Centralized 
manufacturing has very 
high sunk costs-making it 
difficult to justify move to 
RDM 
‘Where it [RDM] doesn’t add value is where you have good 
distribution networks and you have a product that can get through 
those distribution networks in a timeframe that meets the patient 
need but also meets any product restrictions and requirements.’ – 
Senior Director- MNE3 
Duplication of facilities 
and management 
structures in RDM model 
brings higher costs  
‘The cost is probably going to go up, so what's the benefit of having 
a local plant that can do it? Because you've got regulatory issues, 
you've got quality issues, What are the practicalities of running a 
duplicate outfit somewhere else, when you could just make your 
current facility bigger?’ - Commercial Manager-MNE4 
Per unit production costs 
very low in centralized 
model 
There’s a lot of sunk capital in the current technologies, and most of 
that investment has been fully depreciated over the years. The cost of 
making the tablet by conventional means is something like 1 US cent 
or 1 Euro cent. So if 3D printing a tablet costs any more than that, 
there's the question of well, why do it that way if you can do it the 
conventional way?- UK Operations Director-MNE5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5: Theme 2: Exploring the flexibility advantages of RDM 
Code SME 
RDM brings 
production closer 
to the point of 
need 
‘The alternative is, instead of scale up, we look at scale out. So start off 
small and if sales increase you can ramp up your production from scaling 
out, through smaller, more localised facilities, closer to the point of need. 
So rather than having a big centralised facility that’s a long way away from 
potential markets you can locate them closer to where they’re needed’-
Operations Director – SME1                                                                          
RDM model 
applicable for cell 
and gene therapies 
‘Potentially you can use distributed manufacturing with these small items 
such as the cell handling mechanisms that you need for the cell therapies 
or the gene therapy that you are going to be deploying’ –Process 
engineer- SME2 
Personalization of 
medicines can 
offset costs of 
RDM system 
‘You might incur a higher average cost, but because you’re offering a 
customised or personalised product, a medicine that might have additional 
benefits through customisation that then may more than offset the cost 
disadvantage.’ –CEO – SME3  
Currently using 
distributed model 
to send 
pharmaceutical 
products to 
patients 
‘A lot of pharmaceutical products are made centrally… produced           
en-masse for large populations, and then sent out all over the world. But 
what we're looking at is this idea of local manufacturing for local delivery, 
where the idea is to have the technology to package medication in local 
areas, and then dispatch directly out to the customer’ - Director of 
Business and Product Development- SME4 
Customizability of 
RDM offsets costs 
advantage of 
centralized 
production 
‘The key to understanding the attractiveness of 3D printing for the 
pharmaceutical industry …even if the average cost will be higher than for 
a conventional route, is that because we can personalise medicine, 
effectively we can derive greater benefits that then might outweigh the 
added cost as well’.- Managing Direct-SME 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6: Theme 3: Complementarities between centralized production and RDM  
Code MNE SME 
RDM is 
suited to 
the 
production 
of 
biopharma 
products 
‘It will potentially work in biopharma because the 
economies of scale in biopharma manufacturing 
seem to be coming down. So you make biopharma in 
reactors which have capacity. It seems that whereas a 
20,000 litre capacity which used to be the efficient 
manufacturing scale seems to coming down to 2,000, 
or 3,000 litres. Whereas tabletting lines don't seem to 
be getting much smaller in economies of scale.- 
Global procurement transformation lead – MNE1 
 
Mnfg. 
plants can 
be 
distributed 
inside of 
hospitals 
‘There is one model that's been around for decades 
called radio pharmacy, for radioactive medicines. You 
have a mini-manufacturing plant, if you like, and, 
within the space of 15 minutes, you make the 
radioactive pharmaceutical injectable, out of this 
additive manufacturing machine…It's preparing a 
specific pharmaceutical product for a specific patient, at 
a specific dose, at the time of use.’ - Global Operations 
Procurement Director MNE2 
‘But in cell therapy you've got things like the 
CAR-T therapy that's come down the line, and 
smart, small, integrated manufacturing models 
to treat people for autologous therapies for 
cancer treatments. You don't build big factories 
for that; you have a distributed manufacturing 
capability. You'll stick some of these small 
units on the side of a hospital to deliver that 
patient performance’ – Process Engineer-SME2 
RDM is 
suited to 
ATMPs 
and 
Biologics 
but not 
small 
molecule 
drugs 
For ATMPs and biologics it (RDM) might make sense. 
But for small molecules? I would suggest, forget it. 
You're not going to get drug manufacturing to be 
distributed for small molecule products.- Senior 
Director- MNE3 
You need to find things where RDM is 
absolutely pivotal to the viability of the approach 
you're talking, and it could be creating some sort 
of part-plastic, part-cell construction that's 
specific to the patient in the operating theatre, 
you do it real time, it's entirely custom, but it 
involves manufacturing processes that are quite 
complicated, and you're not making thousands a 
minute, you're making one. CEO-SME 3 
RDM 
ideal for 
formulatin
g patient 
specific 
treatments 
on-site at 
the 
hospital 
‘Compounding is an example where, we had some 
discussion within NHS England when they said 
‘Actually what we'd really like you to do is just deliver 
infusion bags ready for patient use. We don't really 
want our pharmacies to have to do that anymore’. That 
would be near-to-hospital, near-to-point-of-use, which 
would be very much personalised to that individual. 
That's an unmet need, definitely.’ –Commercial 
Manager MNE 4 
It works well with these tailored cancer 
treatments.  Quite often what they can do is 
take the bulks to the hospital and then they 
formulate the specific treatment they need for 
that patient there in the hospital, which works 
quite well-Operations Director-SME 1 
RDM 
suited to 
combining 
active 
ingredients 
in one pill 
‘It [3D printing] potentially allows you to put more 
than one drug in to a tablet, which is very difficult at 
the moment. Poly pills are probably going to be the 
way drugs are delivered in the future because modern 
medicine is going to be relying on multiple actives 
rather than single active. Like how you might think in 
terms of, HIV medication is multiple actives.’ – UK 
Operations Director MNE 5 
 
 
 
 
 
 
 
 
 
Table 7- Cross-case comparison of data coding 
Case 
company 
Coding Summary 
 Exploitation (Efficiency) Exploration(flexibility) Complementarities 
MNE 1 Current business model 
based on large volumes 
and low variety-too 
expensive to move to 
RDM model 
 RDM is suited to the 
production of biopharma 
products 
MNE 2 Centralized 
manufacturing offers 
economies of scale 
 Manufacturing plants can be 
distributed inside of hospitals 
MNE 3 Centralized 
manufacturing has very 
high sunk costs-making 
it difficult to justify 
move to RDM 
 RDM is suited to ATMPs and 
Biologics but not small 
molecule generic drugs 
MNE 4 Duplication of facilities 
and management 
structures in RDM 
model brings higher 
costs  
 RDM ideal for formulating 
patient specific treatments on-
site at the hospital 
MNE 5 Per unit production costs 
low in centralized model 
 RDM suited to combining 
active ingredients in one pill 
(poly-pills) 
SME 1  RDM brings 
production closer to 
the point of need 
RDM ideal for formulating 
patient specific treatments on-
site at the hospital 
SME 2  RDM model 
applicable for cell and 
gene therapies 
Manufacturing plants can be 
distributed inside of hospitals 
SME 3  Personalization of 
medicines can offset 
costs of RDM system 
RDM is suited to ATMPs and 
Biologics but not small 
molecule drugs 
SME 4  Currently using 
distributed model to 
send pharmaceutical 
products to patients 
 
SME 5  Customizability of 
RDM offsets costs 
advantage of 
centralized production 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Structurally Partitioned Manufacturing Function in MNEs 
 
 
 
 
Figure 2: Structurally Partitioned MNE Supply Chain 
 
 
 
Figure 3: Contextual ambidexterity of SME’s  
 
 
 
 
 
 
 
 
